Study confirms duodenal mucosa as therapeutic target in T2D
02 Mar 2021
byJairia Dela Cruz
Removing
the excessive layer of the duodenal mucosa via hydrothermal ablation is safe and effective in type 2 diabetes (T2D) patients with or without nonalcoholic liver disease, improving glycaemic control and reducing liver fat content, especially in patients with high fasting plasma glucose, according to the REVITA-2 feasibility trial.